ArticleResearch and practice in thrombosis and haemostasis2026
Mechanism of action and impact on thrombin generation of denecimig (Mim8), emicizumab, and zemocimig (NXT007): comparative analysis using sequence-identical analogs.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Divergent molecular strategies of next-generation activated factor VIII mimetics: insights from a direct comparative analysis.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Activated factor VIII (FVIIIa) mimetic antibodies restore hemostasis in hemophilia A by bridging FIXa and FX. Next-generation mimetics such as denecimig and zemocimig have been optimized for improved hemostatic activity following the launch of emicizumab. However, direct comparisons of available mechanistic data are limited due to heterogeneous experimental conditions. Objectives: This study employed FX activation and thrombin generation assays to assess how the distinct mechanistic properties of the 3 FVIIIa mimetics translate into differences in hemostatic potential. Methods: Sequence-identical analogs (SIAs) of zemocimig and emicizumab were produced recombinantly and purified. FX activation kinetics in the presence of FVIIIa mimetics were assessed across increasing FIXa concentrations, and apparent dissociation constants and specific activity were derived. Thrombin generation assays were performed in hemophilia A platelet-poor plasma triggered with tissue factor, FXIa, or both. Results: Complex assembly affinity was highest for zemocimig-SIA, intermediate for emicizumab-SIA, and lowest for denecimig. In contrast, denecimig demonstrated markedly higher specific activity than both comparators, indicating distinct kinetic behavior. However, the FX activation assay represents a simplified system, and its artificial nature limits broader conclusions regarding physiological coagulation. Thrombin generation assays showed comparable thrombin generation profiles for denecimig and zemocimig-SIA, both exceeding emicizumab-SIA in potency. Conclusion: These data indicate distinct mechanistic strategies among the 3 FVIIIa mimetics, with efficient complex assembly for emicizumab-SIA and zemocimig-SIA versus lower-affinity assembly but higher catalytic activity for denecimig. Despite these differences, zemocimig-SIA and denecimig exhibit comparable thrombin generation potential, supporting similar improvement in hemostatic potential relative to emicizumab-SIA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.